v3.26.1
Segment Information - Schedule of Significant Segment Expenses (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Total revenues $ 2,986.9 $ 2,770.2
Cost of sales 392.8 363.0
Acquired in-process research and development expenses 0.5 19.8
Intangible asset impairment charge 0.0 379.0
Interest income, net (114.8) (117.9)
Provision for income taxes 221.5 84.1
Net income 1,031.4 646.3
Pharmaceuticals    
Segment Reporting Information [Line Items]    
Total revenues 2,986.9 2,770.2
Research expenses 205.0 206.1
Development expenses 756.6 773.6
Acquired in-process research and development expenses 0.5 19.8
Selling and other commercial expenses 313.6 241.1
General and administrative expenses 180.1 155.3
Intangible asset impairment charge 0.0 379.0
Interest income, net (114.8) (117.9)
Other segment items 0.2 19.8
Provision for income taxes 221.5 84.1
Net income 1,031.4 646.3
Products    
Segment Reporting Information [Line Items]    
Total revenues 2,986.9 2,760.2
Products | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Cost of sales 160.2 130.6
Royalty | Pharmaceuticals    
Segment Reporting Information [Line Items]    
Cost of sales $ 232.6 $ 232.4